Identifying Opportunities to Deliver High‐Quality Cancer Care Across a Health System: A Clinical Responsibility

Abstract

ObjectiveWe examined process‐related quality metrics for oral squamous cell carcinoma (OSCC) depending on treating facility type across a health system and region.Study DesignRetrospective in accordance with Strengthening the Reporting of Observational Studies in Epidemiology guidelines.SettingSingle health system and region.MethodsPatients with OSCC diagnosed between 2012 and 2018 were identified from tumor registries of 6 hospitals (1 academic and 5 community) within a single health system. Patients were categorized into 3 care groups: (1) solely at the academic center, (2) solely at community facilities, and (3) combined care at academic and community facilities. Primary outcome measures were process‐related quality metrics: positive surgical margin rate, lymph node yield (LNY), adjuvant treatment initiation ≤6 weeks, National Comprehensive Cancer Network (NCCN)‐guideline adherence.ResultsA total of 499 patients were included: 307 (61.5%) patients in the academic‐only group, 101 (20.2%) in the community‐only group, and 91 (18.2%) in the combined group. Surgery at community hospitals was associated with increased odds of positive surgical margins (11.9% vs 2.5%, odds ratio [OR]: 47.73, 95% confidence interval [CI]: 11.2‐275.86, P < .001) and lower odds of LNY ≥ 18 (52.8% vs 85.9%, OR: 0.15, 95% CI: 0.07‐0.33, P < .001) relative to the academic center. Compared with the academic‐only group, odds of adjuvant treatment initiation ≤6 weeks were lower for the combined group (OR: 0.30, 95% CI: 0.13‐0.64, P = .002) and odds of NCCN guideline‐adherent treatment were lower in the community only group (OR: 0.35, 95% CI: 0.18‐0.70, P = .003).ConclusionQuality of oral cancer care across the health system and region is comparable to or better‐than national standards, indicating good baseline quality of care. Differences by facility type and fragmentation of care present an opportunity for bringing best in‐class cancer care across an entire region.